Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accounts Payables (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Accounts Payables readings, the most recent being $24.4 million for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 1131.18% to $24.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $24.4 million, a 1131.18% increase, with the full-year FY2025 number at $2.0 million, down 0.54% from a year prior.
  • Accounts Payables hit $24.4 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $2.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $24.4 million in Q1 2026 to a low of $648000.0 in Q2 2023.
  • Median Accounts Payables over the past 5 years was $3.4 million (2022), compared with a mean of $5.5 million.
  • Biggest five-year swings in Accounts Payables: crashed 75.27% in 2024 and later skyrocketed 1131.18% in 2026.
  • Kiniksa Pharmaceuticals International's Accounts Payables stood at $7.9 million in 2022, then grew by 4.39% to $8.2 million in 2023, then crashed by 75.27% to $2.0 million in 2024, then dropped by 0.54% to $2.0 million in 2025, then surged by 1103.25% to $24.4 million in 2026.
  • The last three reported values for Accounts Payables were $24.4 million (Q1 2026), $2.0 million (Q4 2025), and $6.1 million (Q3 2025) per Business Quant data.